Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Generic drugmaker to pay $3m antitrust fine

5 December 2019 New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.

Americas

Judge gives initial approval to Actavis $20m antitrust deal

15 September 2020 A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More on this story

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Generic drugmaker to pay $3m antitrust fine

5 December 2019 New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.

Americas

Judge gives initial approval to Actavis $20m antitrust deal

15 September 2020 A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More on this story

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Generic drugmaker to pay $3m antitrust fine

5 December 2019 New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.

Americas

Judge gives initial approval to Actavis $20m antitrust deal

15 September 2020 A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More features

President Trump 2.0: Five major areas to watch

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features